Guilin Pharmaceutical Co., Ltd

Form 483 issued March 13, 2015 · Guilin, China

Inspection
Mar 9 – Mar 13, 2015
Investigator
Steven D. Kehoe
Observations
1
Pages
1
FEI number
3002807125

In short: On March 13, 2015, FDA issued a Form 483 with 1 observation to Guilin Pharmaceutical Co., Ltd in Guilin, China (FEI 3002807125) after an inspection that ran Mar 9 – Mar 13, 2015. The investigator was Steven D. Kehoe. Most observations concern quality system; the most-cited regulation is 21 CFR 211.192 (production record review).

At a glance

1 of 1 observations on this 483 concern quality system.

Quality system1

Most cited: 21 CFR 211.192 (1×) · 211.100 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Investigations into observed discrepancies do not always include corrective and preventive actions which fully address the…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Guilin Pharmaceutical Co., Ltd?

FDA listed 1 observation on this Form 483, mostly about quality system. The most-cited regulation is 21 CFR 211.192 (production record review). The opening words of each observation are shown on this page.

Who inspected Guilin Pharmaceutical Co., Ltd?

Steven D. Kehoe is named on this Form 483, for the inspection of Mar 9 – Mar 13, 2015. Each investigator has a profile showing what they cite most.

When was Guilin Pharmaceutical Co., Ltd inspected by FDA?

The inspection ran Mar 9 – Mar 13, 2015, and the Form 483 is dated March 13, 2015.

How do I get the full Form 483 for Guilin Pharmaceutical Co., Ltd?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free